Profile: OraPharma, Inc. specializes in oral health care. We discover, develop and commercialize therapeutics for oral health. We specialize in the production of Arestinr, which represents a promising therapeutic advance for the adjunct treatment of periodontal disease. It is a locally administered time-released antibiotic encapsulated in micro spheres that effectively kills the germs that cause periodontal disease or periodontitis. It contains microspheres that are filled with antibiotic minocycline & release the drug into the infected periodontal pocket, which kills the bacteria. It reduces pocket depths, kills the bacteria associated with periodontal disease and decreases bleeding on probing. These microspheres continue to fight the infection for up to 21 days after scaling & root planning.